EPP photoprotection
Adults with erythropoietic protoporphyria experience painful phototoxic reactions to visible light.
Explore the research →MC1R & PHOTOPROTECTION MEDICINE
Afamelanotide
A specialist medicine that increases skin pigmentation and helps people with EPP spend longer in light with less pain.
EPP photoprotectionMC1R signallingEumelanin
An approved peptide medicine with a narrow, specialist indicationAfamelanotide has randomized human efficacy data and regulatory approval for adult EPP. That evidence does not validate cosmetic tanning, unapproved powders or self-injection.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Where does Afamelanotide have credible benefit?
Afamelanotide shows how powerful the body's pigmentation pathway can be when used for a clear medical purpose. By increasing protective eumelanin, it can help people with EPP spend more time in daylight without severe pain — a benefit that can make an enormous difference to everyday life.
MC1R and eumelanin
Afamelanotide activates melanocortin-1 receptors and increases protective eumelanin production.
Explore the research →More pain-free daylight
The practical EPP goal is greater freedom for daily activity rather than simply darker skin.
Explore the research →Vitiligo repigmentation research
A small randomized study combined four monthly implants with narrowband UV-B phototherapy.
Explore the research →THE SCIENCE BIT
Turning on the skin's pigment pathway.
Afamelanotide is an analogue of alpha-MSH that activates the melanocortin-1 receptor, MC1R. This stimulates production of eumelanin, the darker form of skin pigment.
The approved implant is used to improve pain-free light exposure in adults with EPP. That defined benefit does not make all sunlight harmless or establish a cosmetic tanning regimen.
See the studies & trials →- MC1R
- Melanocortin-1 receptor
- Melanocytes
- Pigment-producing cells
- Eumelanin
- The darker pigment
How this connects to the research
Established mechanism and a specific authorised clinical indication.
FROM MOLECULE TO TISSUE
Where Afamelanotide connects with the body
These are the tissues and biological systems behind the interest in Afamelanotide.
- Skin
- Melanocyte signalling.
- Pigment granules
- Eumelanin production.
- EPP context
- Measured light-tolerance benefit.
The research behind the interest
EPP photoprotection
Adults with erythropoietic protoporphyria experience painful phototoxic reactions to visible light.
Randomized trials and regulatory reviews found that afamelanotide increased pain-free light exposure, although the benefit is meaningful rather than curative.
Established human efficacy in EPPExplore the studies →MC1R and eumelanin
Afamelanotide activates melanocortin-1 receptors and increases protective eumelanin production.
The mechanism explains pigmentation and photoprotection but does not make UV exposure harmless or remove the need for sun and light precautions.
Established mechanismExplore the studies →More pain-free daylight
The practical EPP goal is greater freedom for daily activity rather than simply darker skin.
In an EMA-reviewed study, participants receiving afamelanotide spent more pain-free time in direct sunlight over six months than those receiving placebo.
Regulatory-reviewed human benefitExplore the studies →Vitiligo repigmentation research
A small randomized study combined four monthly implants with narrowband UV-B phototherapy.
The combination produced faster and greater repigmentation than NB-UVB alone, but vitiligo remains an unapproved indication and requires dermatology oversight.
Promising off-label human evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableAfamelanotide for erythropoietic protoporphyria ↗
Adults with erythropoietic protoporphyria in European and US studies
Subcutaneous bioresorbable implant16 mg every two months during the study periodUp to six months
Afamelanotide increased pain-free time in sunlight and improved disease-specific quality-of-life measures.
The trials support the approved EPP indication; they do not validate cosmetic tanning use.
Afamelanotide plus narrowband UV-B phototherapy for vitiligo ↗
55 adults with stable or slowly progressive nonsegmental vitiligo
16 mg subcutaneous implantMonthly for four months alongside NB-UVBFour-month treatment with follow-up
Combination treatment produced faster and greater repigmentation than NB-UVB alone, particularly in darker skin phototypes.
This was a small study and does not create an approved vitiligo indication or a home-use protocol.
European regulatory assessment and continuing monitoring ↗
Adults with confirmed erythropoietic protoporphyria
Specialist-administered subcutaneous implant
EMA describes increased pain-free light exposure and continued authorization under exceptional circumstances.
The product information sets dose frequency, monitoring and use restrictions; it is not a cosmetic product.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceExtensive
5/5 evidence depth
Randomized EPP trials and continuing clinical use provide substantial human evidence.
✓
Clinical efficacyExtensive
5/5 evidence depth
Pain-free light exposure in adults with EPP is an established, regulator-reviewed benefit.
◇
Safety evidenceStrong
4/5 evidence depth
Clinical safety and monitoring information exist, though long-term surveillance and specialist administration remain important.
⌁
Preclinical evidenceStrong
4/5 evidence depth
Melanocortin, pigmentation and photoprotection mechanisms are supported by extensive laboratory and translational research.
HOW TO READ THESE SCORESStrong preclinical evidence · extensive human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
EVIDENCE LANDSCAPEAfamelanotideMechanism → measured response → clinical outcome
Randomized multicentre EPP trials
Increased pain-free light exposure in adult EPP
Evidence does not validate tanning powders or injections
Keep route, study setting and outcome together
A measured biological response can be valuable evidence without establishing a self-administered protocol or a durable treatment benefit.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Afamelanotide
Afamelanotide attracts interest in EPP, photoprotection, vitiligo and pigmentation. Its approved implant evidence is valuable precisely because it should not be blurred with unapproved tanning injections or internet powders.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
More freedom in daylight with EPP
For people with erythropoietic protoporphyria, the goal is spending time outside with less phototoxic pain. This is a specific quality-of-life benefit in a defined condition.
- What makes a report informative
- Pain-free daylight exposure and daily participation in the studied setting.
- What can muddy the picture
- Licensed implant evidence is specific to the product and indication.
Pigmentation and photoprotection interest
The melanin-related mechanism attracts interest beyond EPP, including a more pigmented appearance. Skin colour and protection from light-related harm are different outcomes.
- What makes a report informative
- The exact indication and outcome being discussed.
- What can muddy the picture
- A darker appearance does not establish protection from sun damage.
Vitiligo-related repigmentation
Combination research attracts people interested in restoring pigment in affected skin. The relevant context includes the accompanying treatment, rather than attributing repigmentation to the peptide alone.
- What makes a report informative
- Affected-area change and the full dermatology regimen.
- What can muddy the picture
- Research with phototherapy cannot be applied directly to unregulated powder or cosmetic use.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Living more freely with EPP
People with EPP value ordinary daylight activities that can otherwise trigger severe pain.
Human findings & limits
Randomized trials and regulatory review show increased pain-free light exposure in adults with EPP.
Laboratory & animal context
MC1R activation and eumelanin biology support the effect.
What this means: A demonstrated benefit within a narrow specialist indication.
Photoprotection
The darker pigmentation is often treated as a visible marker of increased eumelanin.
Human findings & limits
Clinical benefit was measured as pain-free light exposure, not immunity from light injury.
Laboratory & animal context
Eumelanin can absorb and disperse radiation-related energy.
What this means: Useful protection for EPP, not permission to abandon sun safety.
Vitiligo repigmentation
Interest follows the trial combining implants with controlled NB-UVB.
Human findings & limits
A 55-person randomized study reported faster and greater repigmentation than NB-UVB alone.
Laboratory & animal context
Melanocortin signalling offers a pigmentation rationale.
What this means: Promising off-label research requiring dermatology oversight and confirmation.
Cosmetic tanning
Online discussion sometimes groups afamelanotide with Melanotan products or unapproved injections.
Human findings & limits
The authorised product is a 16 mg implant for adult EPP, not a self-injected cosmetic regimen.
Laboratory & animal context
Pigmentation biology does not establish a favourable cosmetic risk–benefit balance.
What this means: Do not transfer the approved EPP evidence to unregulated tanning products.
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
ONE ANECDOTAL COMMUNITY EXAMPLE
ANECDOTAL · UNVALIDATEDA fixed implant schedule—there is no titration
The authorised product is a 16 mg bioresorbable implant placed by trained healthcare professionals for adults with EPP.
1Before higher light
16 mg implantConfirm EPP, suitability and skin baseline
2Two months later
16 mg implantRepeat only within specialist care
3Two months later
16 mg implantTypical third EU seasonal implant
4Clinical review
Continue or stopEU maximum is four implants per year
What the authorised schedule describesOne 16 mg subcutaneous implant every two months; EU guidance usually recommends three per year and no more than four.
What it does not validateThere is no approved cosmetic-tanning injection, powder conversion, self-implantation method or dose escalation.
ROUTE & DELIVERYAn implant is not an injectable vial
SCENESSE is a sterile, bioresorbable rod inserted subcutaneously by a trained professional. Milligram comparisons with unregulated tanning products are inappropriate.
PROFESSIONAL SOURCE CONTEXT
EMA Scenesse product information ↗The source provides the authorised EPP indication, fixed implant amount, interval and monitoring requirements.
Afamelanotide has an authorised 16 mg implant schedule for adult EPP; there is no approved cosmetic-tanning or self-injection regimen.
PUBLISHED HUMAN RESEARCH
View source ↗US FDA-approved EPP schedule ↗
Adults with a history of phototoxic reactions from EPP
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved Adults with a history of phototoxic reactions from EPP. Route: Implant placed under the skin by a trained healthcare professional. The study lasted ongoing only under specialist review. The figures below describe the research design, not a personal schedule.
| First amount studied | 16 mg implant |
|---|---|
| How often? | Every two months |
| How was it given? | Implant placed under the skin by a trained healthcare professional |
| How long? | Ongoing only under specialist review |
See the exact study wording +
Start / initial: 16 mg implant
End / target: 16 mg implant
Frequency: Every two months
Route: Subcutaneous implant placed by a trained healthcare professional
Study duration: Ongoing only under specialist review
Source: FDA prescribing information ↗
No titration is described. Maintain light-protection measures and twice-yearly full-body skin examinations.
PUBLISHED HUMAN RESEARCH
View source ↗EU seasonal EPP schedule ↗
Adults with confirmed EPP
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved Adults with confirmed EPP. Route: Implant placed under the skin in specialist care. The study lasted usually three implants per year; maximum four. The figures below describe the research design, not a personal schedule.
| First amount studied | 16 mg implant |
|---|---|
| How often? | Every two months before and during higher light exposure |
| How was it given? | Implant placed under the skin in specialist care |
| How long? | Usually three implants per year; maximum four |
See the exact study wording +
Start / initial: 16 mg implant
End / target: 16 mg implant
Frequency: Every two months before and during higher light exposure
Route: Specialist subcutaneous implant
Study duration: Usually three implants per year; maximum four
Source: EMA product information ↗
EU guidance places treatment in designated specialist centres and recommends observation after implantation.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Specialist implant appointment guide
Licensed product · specialist administrationScenesse is an implant administered by trained specialists for its licensed indication. Its two-month interval means calendar months, which cannot be replaced by a fixed 60-day interval. Use the test/review reminder for the actual appointment date; research-vial injection amounts are not equivalent.
Form and route: Scenesse 16 mg subcutaneous implant
The planner keeps amounts and repeat patterns blank for this compound. Use its formulation guide to record an independently specified schedule.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Often combined with
OFTEN COMBINED WITH
Community rationale · component roles · evidence boundaryWhy people explore pairings with Afamelanotide
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Potential first, evidence in context. Pairings are usually explored because their research stories appear complementary. That makes them interesting to study, but does not yet prove extra benefit or safety.
CURRENT COMPOUNDAfamelanotide
→
OFTEN EXPLORED WITHAfamelanotide + EPP light protection
Afamelanotide implant + Protective clothing, shade and planned exposure
→
OFTEN EXPLORED WITHAfamelanotide + narrowband UV-B
Afamelanotide implant + Dermatologist-delivered NB-UVB
→
OFTEN EXPLORED WITHAfamelanotide + skin monitoring
Afamelanotide + Full-body pigment-lesion examination
Combination-specific human research is the strongest evidence for what a pairing adds. Evidence for either ingredient alone should not be silently transferred to the combination.
AAFAMELANOTIDE IS USUALLY DISCUSSED AROUNDApproved MC1R-driven photoprotection for adult EPP
＋The evidence supports a specialist 16 mg implant, continued light protection and skin monitoring—not general tanning use.
PTHE PAIRED APPROACH MAY ADDPractical EPP protection or dermatologist-controlled NB-UVB
Light precautions belong to approved care; NB-UVB combination evidence is limited to a small off-label vitiligo trial.
＋
OFTEN EXPLORED WITH
Explore →＋Afamelanotide + EPP light protection
Afamelanotide implant + Protective clothing, shade and planned exposureWHY IT IS EXPLOREDThe medicine can increase light tolerance, while practical protection still reduces avoidable phototoxic exposure.
This is the appropriate approved-care context; afamelanotide does not replace sun and light precautions.OFTEN EXPLORED WITH
Explore →＋Afamelanotide + narrowband UV-B
Afamelanotide implant + Dermatologist-delivered NB-UVBWHY IT IS EXPLOREDA small randomized vitiligo study found faster and greater repigmentation with the combination.
Vitiligo use remains unapproved and requires specialist assessment, dose control and skin surveillance.OFTEN EXPLORED WITH
Explore →Afamelanotide + skin monitoring
Afamelanotide + Full-body pigment-lesion examinationWHY IT IS EXPLOREDDarkening of existing moles and freckles can occur, making baseline and follow-up inspection important.
US prescribing information recommends full-body skin examination twice yearly.01Keep the indication visible
EPP photoprotection, vitiligo treatment and cosmetic tanning have different evidence and risk–benefit balances.
02Do not substitute Melanotan products
Unapproved powders and injections are not equivalent to the regulated implant.
03Build in skin surveillance
Pigment changes require baseline and follow-up full-body examination.
Safety context
SAFETY & UNCERTAINTY
Approved does not mean appropriate for cosmetic or unsupervised use
01ENCOURAGING CONTEXTBenefit is established for adult EPP
Randomized trials and regulatory review support increased pain-free light exposure using the approved implant.
02THE IMPORTANT BOUNDARYThe indication is not cosmetic tanning
A specialist 16 mg implant cannot validate unapproved powder, self-injection or Melanotan products.
03WHAT STILL NEEDS MONITORINGPigment lesions and individual suitability
Skin changes, implant reactions, medicines, pregnancy and liver or kidney status require professional review.
What the current evidence saysImplant-site reactions, nausea, headache and skin darkening can occur. Existing and new pigment lesions require monitoring, light protection must continue, and treatment belongs with trained specialist teams. Reduced liver or kidney function is a restriction in European product information; pregnancy, anticoagulants and individual suitability require clinician review.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Darkening of existing moles and freckles can occur; new or changing pigmented lesions need review.
Protective clothing, shade and EPP light-management measures remain necessary during treatment.
The approved bioresorbable rod is inserted by trained professionals and is not equivalent to a vial or tanning injection.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
7 sourcesSources used on this profile
Original publicationAfamelanotide for erythropoietic protoporphyriaJournal / DOI ↗Bibliographic recordAfamelanotide for erythropoietic protoporphyriaPubMed ↗Original publicationAfamelanotide plus narrowband UV-B phototherapy for vitiligoJournal / DOI ↗Bibliographic recordAfamelanotide plus narrowband UV-B phototherapy for vitiligoPubMed ↗European regulatory sourceEuropean regulatory assessment and continuing monitoringEMA EPAR and product information ↗Published dosing contextUS FDA-approved EPP scheduleFDA prescribing information ↗Professional sourceUnited KingdomMHRA products database ↗
CURRENT STATUS
How to interpret its position today
Authorised for adults with EPP under exceptional circumstances
SCENESSE is a 16 mg implant administered in designated specialist centres to increase pain-free light exposure. Current product information and national availability should be checked.
EMA EPAR ↗FDA approved for adults with EPP
The approved indication is increased pain-free light exposure in adults with a history of phototoxic reactions from EPP. The implant is administered by a trained healthcare professional.
FDA prescribing information ↗Confirm current access with a specialist porphyria service
EU authorisation does not by itself describe current UK commissioning or access. Check the MHRA products database and a UK porphyria specialist rather than assuming availability.
MHRA products database ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.